In this special Pulmonary & Nasal Drug Delivery issue, experts from Aptar Pharma, Nanopharm and Noble have contributed three interesting articles:
- “Is Now the Time to Shake Up the pMDI Environment?” by Chris Baron, Director Business Development, Rx, EMEA at Aptar Pharma.
This article explores how the use of propellants in pressurised metered dose inhalers has evolved – and how alternative propellants could be a catalyst for greater patient adherence.
- “Developing an In Vitro Dissolution and Release System for Orally Inhaled Drug Products” by Rob Price, Chief Scientific Officer, Nanopharm Ltd, an Aptar Pharma company.
This article critiques regulatory routes for the development of generic OINDPs, runs through recent announcements and developments of note from regulators, and describes how Nanopharm has pioneered the concept of structural Q3 equivalence.
- “Be prepared. The Importance of Training and Onboarding Programs for Intranasal Rescue Therapies” by Joe Masci, Executive Director of Business Development Noble International, an Aptar Pharma company.
With a recent resurgence in nasal drug repurposing, this article looks at the importance of training and onboarding for intranasal rescue therapies.